ACM
FLGT icon

Anfield Capital Management’s Fulgent Genetics FLGT Stock Holding History

Anfield Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7
Closed -$1K – 112
2021
Q3 		$1K Buy
+7
New +$636 ﹤0.01% 111

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Anfield Capital Management's FLGT Position: Q4 2021 in Review

Anfield Capital Management sold out of Fulgent Genetics (FLGT) in Q4 2021, closing a stake of 7 shares — an estimated $1K sold.

Anfield Capital Management first reported a position in FLGT in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 299 funds tracked by Wall St. Rank hold FLGT as of Q4 2021.

  • Anfield Capital Management reported no remaining Fulgent Genetics position as of Q4 2021 after selling out during the quarter.
  • Anfield Capital Management sold 7 Fulgent Genetics shares in Q4 2021, an estimated $1K.
  • Anfield Capital Management first reported a position in Fulgent Genetics in Q3 2021 and held it in 1 quarter.
  • Anfield Capital Management's Fulgent Genetics position peaked at $1K in Q3 2021.
  • 299 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2021.

Based on Anfield Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.